

Status: Point in time view as at 31/12/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2017/1000. (See end of Document for details)

ANNEX

In Annex XVII to Regulation (EC) No 1907/2006, the following entry is added:

<p>68. Perfluorooctanoic acid (PFOA) CAS No 335-67-1 EC No 206-397-9 and its salts. Any related substance (including its salts and polymers) having a linear or branched perfluoroheptyl group with the formula C_7F_{15}- directly attached to another carbon atom, as one of the structural elements. Any related substance (including its salts and polymers) having a linear or branched perfluorooctyl group with the formula C_8F_{17}- as one of the structural elements. The following substances are excluded from this designation: — $C_8F_{17}-X$, where $X = F, Cl, Br$. — $C_8F_{17}-C(=O)OH$, $C_8F_{17}-C(=O)O-X$ ' or $C_8F_{17}-CF_2-X'$ (where X' = any group, including salts).</p>	<p>1. Shall not be manufactured, or placed on the market as substances on their own from 4 July 2020.</p> <p>2. Shall not, from 4 July 2020, be used in the production of, or placed on the market in: (a) another substance, as a constituent; (b) a mixture; (c) an article, in a concentration equal to or above 25 ppb of PFOA including its salts or 1 000 ppb of one or a combination of PFOA-related substances.</p> <p>3. Points 1 and 2 shall apply from: (a) 4 July 2022 to: (i) equipment used to manufacture semi-conductors; (ii) latex printing inks. (b) 4 July 2023 to: (i) textiles for the protection of workers from risks to their health and safety; (ii) membranes intended for use in medical textiles, filtration in water treatment, production processes and effluent treatment; (iii) plasma nano-coatings. (c) 4 July 2032 to medical devices other than implantable medical devices within the scope of Directive 93/42/EEC.</p> <p>4. Points 1 and 2 shall not apply to any of the following: (a) perfluorooctane sulfonic acid and its derivatives, which are listed in Part A of Annex I to Regulation (EC) No 850/2004; (b) the manufacture of a substance where this occurs as an unavoidable by-product of the manufacture of fluorochemicals with a carbon chain equal to or shorter than 6 atoms;</p>
---	--

Status: Point in time view as at 31/12/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) 2017/1000. (See end of Document for details)

- (c) a substance that is to be used, or is used as a transported isolated intermediate, provided that the conditions in points (a) to (f) of Article 18(4) of this Regulation are met;
 - (d) a substance, constituent of another substance or mixture that is to be used, or is used:
 - (i) in the production of implantable medical devices within the scope of Directive 93/42/EEC;
 - (ii) in photographic coatings applied to films, papers or printing plates;
 - (iii) in photo-lithography processes for semiconductors or in etching processes for compound semiconductors;
 - (e) concentrated fire-fighting foam mixtures that were placed on the market before 4 July 2020 and are to be used, or are used in the production of other fire-fighting foam mixtures.
5. Point 2(b) shall not apply to fire-fighting foam mixtures which were:
- (a) placed on the market before 4 July 2020; or
 - (b) produced in accordance with point 4(e), provided that, where they are used for training purposes, emissions to the environment are minimised and effluents collected are safely disposed of.
6. Point 2(c) shall not apply to:
- (a) articles placed on the market before 4 July 2020;
 - (b) implantable medical devices produced in accordance with point 4(d)(i);
 - (c) articles coated with the photographic coatings referred to in point 4(d)(ii);
 - (d) semiconductors or compound semiconductors referred to in point 4(d)(iii).

Status:

Point in time view as at 31/12/2020.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EU) 2017/1000.